drugset / Trial / NCT06732583
A Study to Evaluate the Safety and Immunogenicity of Ad5-105K in Adults Aged 18 to 49 Years
Phase 1
Active not recruiting
36 enrolled
CanSino Biologics Inc.
PT Etana Biotechnologies Indonesia · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This is a randomized, observer-blind, positive-controlled study. There will be 2 treatment groups (Group A and B). In each treatment group, 18 participants will be randomly assigned to receive either the investigational vaccine (Dose A or Dose B of Ad5-105K) or a placebo in a ratio of 2:1. The distribution of participant's gender and age should be balanced in each group.
Timeline
- Start
- 2025-11-13
- Primary completion
- 2026-08
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ad5-105K | Vaccine | 1e+08 unknown | Inhaled |
| Subject | Ad5-105K | Vaccine | 2e+08 unknown | Inhaled |